Promoting Treatment Adherence in nAMD and DME


Experts conclude the series with the hope that longer-acting agents will lead to better real-world outcomes for patients, mirroring clinical trial results and potentially preventing vision loss, especially in countries with limited access to healthcare.


Experts conclude their discussion reflecting on recent therapeutic advancements and novel approaches on the horizon. As the use of longer durability agents increases, there's optimism that patient adherence to treatment will improve, potentially leading to better real-world outcomes compared to clinical trials. Educating patients about the importance of regular follow-ups and the ongoing nature of treatment is crucial for maintaining adherence. Visual aids like OCT scans can motivate patients by showing the reduction of fluid and improvement in their condition over time. Ultimately, fostering patient buy-in early on and providing ongoing support are key to maximizing treatment effectiveness and preserving vision in conditions like neovascular AMD and diabetic macular edema.

This summary was AI-generated and edited for clarity.

Related Videos
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.